<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341871</url>
  </required_header>
  <id_info>
    <org_study_id>P16-570</org_study_id>
    <nct_id>NCT03341871</nct_id>
  </id_info>
  <brief_title>Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6</brief_title>
  <official_title>Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, post-marketing, observational study evaluates the real world safety and&#xD;
      effectiveness of glecaprevir plus pibrentasvir use in participants infected with the&#xD;
      hepatitis C virus genotype 1 - 6.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Actual">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 weeks after last dose of drug</time_frame>
    <description>SVR12 defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level &lt; the lower limit of quantification (LLOQ) 12 weeks after the last dose of Glecaprevir plus Pibrentasvir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Post-treatment Relapse</measure>
    <time_frame>Up to 24 weeks after last dose of drug</time_frame>
    <description>Post-treatment relapse was defined as confirmed HCV RNA &gt;= LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels &lt; LLOQ at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with On-treatment Virologic Failure</measure>
    <time_frame>Up to 12 weeks after first dose</time_frame>
    <description>On-treatment virologic failure was defined as HCV RNA levels reach &lt; LLOQ during treatment then increase to &gt;= LLOQ during treatment, or confirmed increase of &gt; 1 log10 IU/mL above the lowest value post-baseline HCV RNA during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR4</measure>
    <time_frame>4 weeks after last dose</time_frame>
    <description>SVR4 defined as defined as the HCV RNA level &lt; LLOQ 4 weeks after the last dose of Glecaprevir plus Pibrentasvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR8</measure>
    <time_frame>8 weeks after last dose of drug</time_frame>
    <description>SVR8 defined as defined as the HCV RNA level &lt; LLOQ 8 weeks after the last dose of Glecaprevir plus Pibrentasvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR24</measure>
    <time_frame>24 weeks after last dose of drug</time_frame>
    <description>SVR24 defined as the HCV RNA level &lt; LLOQ 24 weeks after the last dose of Glecaprevir plus Pibrentasvir.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1095</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>HCV Genotypes 1, 2, 3, 4, 5, or 6 participants</arm_group_label>
    <description>Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Japan patients infected with hepatitis C virus and treating with glecaprevir plus&#xD;
        pibrentasvir per approved Japan label.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic hepatitis C virus infection and administering glecaprevir plus&#xD;
             pibrentasvir.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated with glecaprevir plus pibrentasvir.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbvie Japan /ID# 161985</name>
      <address>
        <city>Tokyo</city>
        <zip>108-6302</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.abbvie.com/content/dam/abbvie-dotcom/us/clinical-trials/ombitasvir_dasabuvir_P16-570.pdf</url>
    <description>clinical study report synopsis</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic hepatitis C virus (HCV)</keyword>
  <keyword>Genotype</keyword>
  <keyword>glecaprevir</keyword>
  <keyword>pibrentasvir</keyword>
  <keyword>sustained virologic response</keyword>
  <keyword>chronic hepatitis C virus genotype 1</keyword>
  <keyword>chronic hepatitis C virus genotype 2</keyword>
  <keyword>chronic hepatitis C virus genotype 3</keyword>
  <keyword>chronic hepatitis C virus genotype 4</keyword>
  <keyword>chronic hepatitis C virus genotype 5</keyword>
  <keyword>chronic hepatitis C virus genotype 6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

